Nephroprotective effect of blockers 3 GMCO-reductase in patients with acute coronary syndrome, after myocardial revascularization by the method of the transgular coronary intervention

Author(s):  O.A. Osipova, Dr., Prof., Belgorod National Research University, Belgorod, Russia, osipova_75@inbox.ru

E.V. Dobromirovа, Belgorod National Research University, Belgorod, Russia

A.I. Golovin, Belgorod National Research University, Belgorod, Russia

O.N. Belousova, candidate of Sciences, no, Belgorod National Research University, Belgorod, Russia

Issue:  Volume 42, № 3

Rubric:  Cardiology

Annotation:  This literature review presents current data on 3-hydroxy-3-methylglutaryl-CoAreductase inhibitors - statins, as anti-inflammatory agents during atherogenesis. Molecular mechanisms responsible for the anti-inflammatory effects of statins are described, as well as clinical data on the non-lipid-lowering effect of statins on cardiovascular outcomes. Analyzed the results of a number of randomized clinical trials, including GREACE, ALLIANCE, TNT, PLANET I, PLANET II and meta-analyzes. Since, cardiovascular events and renal dysfunction are associated with increased morbidity, reduced quality of life and higher mortality rates. The prospects for further research are discussed to compare the clinical efficacy of statins (atorvastatin and rosuvastatin) in patients with acute coronary syndrome with ST elevation. The possible role of statins on endothelial cell function is discussed. The pleiotropic effects of the new generation of statins are actively explained. The possibility of the active use of statins in groups of patients of middle and senile age was also discussed.

Keywords:  acute coronary syndrome, statins, chronic kidney disease

Full text (PDF):  Download

Downloads count:  342